Teva Pharmaceutical Industries Ltd. (TEVA) surged 5.41% in pre-market trading on Wednesday, driven by the company's better-than-expected first-quarter 2026 financial results and the announcement of a strategic acquisition.

The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst estimates of $0.48. Revenue reached $3.982 billion, exceeding expectations of $3.810 billion and representing a 2.34% increase year-over-year. The strong performance was attributed to growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year.

Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million, adding a first-in-class therapy for Tourette syndrome to its neuroscience pipeline. The company maintained its 2026 business outlook while updating it to reflect the Emalex transaction, demonstrating confidence in its continued growth trajectory under its "Pivot to Growth" strategy.